As India opens up to new testing methods for Covid-19, approvals for importing kits, which use technology other than rapid antibody tests that rely on immunoglobulins, have received the drug regulator’s nod. Some of these kits would use chemiluminescent platforms, while others would use ELISA (enzyme-linked immunosorbent assay) platforms.
Multinationals, such as Abbott Healthcare and Roche Diagnostics, have received approval to import such kits. The controversy around the efficacy and the pricing of rapid tests has encouraged government agencies to look for other testing methods that would be relatively accurate as the country heads towards a graded exit plan from